Cardiff Oncology Inc v. Nerviano Medical Sciences SRL

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Cardiff Oncology, Inc. (Delaware)
  • Defendant: Nerviano Medical Sciences S.r.l. (Italy)
  • Plaintiff's Counsel: Sheppard, Mullin, Richter & Hampton LLP
• Case Identification: Cardiff Oncology, Inc. v. Nerviano Medical Sciences S.r.l., 3:26-cv-03131, S.D. Cal., 07/17/2026
• Venue Allegations: Plaintiff alleges venue is proper in the Southern District of California because a substantial part of the events giving rise to the claims, including the conception and reduction to practice of the patented inventions, occurred in the district.
• Core Dispute: Plaintiff seeks a declaratory judgment that it did not breach a license agreement with Defendant and that its employees are the sole correct inventors of two U.S. patents, following Defendant's demand to add its own employee as an inventor and its subsequent attempt to terminate the license agreement.
• Technical Context: The technology involves combination cancer therapies using a PLK1 inhibitor (onvansertib) with an anti-angiogenic drug to treat metastatic cancers, a field with significant unmet medical need.
• Key Procedural History: The dispute arises from a 2017 License Agreement under which Plaintiff Cardiff Oncology licensed the drug candidate onvansertib from Defendant NMS. Cardiff subsequently developed and patented new methods of using the drug. The complaint alleges that NMS demanded its employee be added as a co-inventor to these patents, and when Cardiff refused, NMS claimed a material breach and purported to terminate the license agreement, prompting this lawsuit.

Case Timeline

Date	Event
2017-03-13	License Agreement between Cardiff and NMS becomes effective.
2022-09-11	Earliest priority date for the '813 and '173 Patents (provisional application filing).
2024-09-01	(approx.) NMS allegedly begins campaign to demand extension of royalty term.
2024-11-19	U.S. Patent No. 12,144,813 issues.
2025-04-01	U.S. Patent No. 12,263,173 issues.
2025-12-18	NMS sends letter to Cardiff alleging its employee contributed to conception.
2026-02-18	NMS claims Cardiff is in material breach for failing to correct inventorship.
2026-04-20	NMS sends letter purporting to terminate the License Agreement.
2026-05-19	Cardiff files its original complaint in this action.
2026-05-27	NMS sends a second purported termination letter to Cardiff.
2026-07-08	NMS sends a "Veto" letter to Cardiff purporting to forbear enforcement pending litigation.
2026-07-17	Plaintiff Cardiff files First Amended Complaint.

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,144,813 - PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer

The Invention Explained

• Problem Addressed: The patent's background section notes that advanced, metastatic cancers have poor prognoses and that there is a need for more effective treatments, as several existing anti-cancer agents have limitations. ('813 Patent, col. 1:40-48).
• The Patented Solution: The patent discloses methods for treating metastatic cancer by administering a combination of a Polo-like kinase 1 (PLK1) inhibitor, such as onvansertib, and an anti-angiogenic agent, such as bevacizumab. ('813 Patent, abstract). The invention is particularly directed to administering this combination to patients who have not previously been treated with an anti-angiogenic drug, a patient population in which the therapy is described as having surprisingly enhanced efficacy. ('813 Patent, col. 18:1-21). Figure 1 of the patent, a Kaplan-Meier survival curve, purports to illustrate the improved progression-free survival (PFS) in patients who had not received prior bevacizumab ("No Prior Bev") compared to those who had ("Prior Bev"). ('813 Patent, FIG. 1).
• Technical Importance: The claimed method is presented as significant because it identifies a specific patient sub-population (anti-angiogenic-naïve) that may derive unexpectedly high benefit from the combination therapy, a counterintuitive finding given that prior art suggested previous bevacizumab treatment did not negatively impact second-line therapy outcomes. ('813 Patent, col. 39:50-59).

Key Claims at a Glance

• The complaint focuses on the "Cardiff Patents" generally but the dispute centers on the invention claimed within them. ('813 Patent, claim 1) is a representative independent claim.
• Essential elements of independent claim 1 of the '813 Patent include:
  • A method of treating a KRAS-mutated metastatic colorectal cancer.
  • Selecting a patient who has not received any prior treatment for the cancer and has not received any prior treatment with bevacizumab.
  • Administering an effective amount of onvansertib and bevacizumab in combination with a chemotherapy containing fluorouracil.
  • Wherein onvansertib and bevacizumab are administered in multiple doses during a treatment cycle.
• The complaint does not specify assertion of dependent claims.

U.S. Patent No. 12,263,173 - PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer

The Invention Explained

• Problem Addressed: The patent addresses the need for more effective treatments for metastatic cancers, which remain a leading cause of death. ('173 Patent, col. 1:40-48).
• The Patented Solution: The patent describes a method of selecting patients for treatment with onvansertib and bevacizumab. The method involves determining if a subject has or has not received prior treatment with bevacizumab. If the subject has not received such prior treatment, they are selected for the combination therapy, which is asserted to reduce or inhibit the progression of metastatic colorectal cancer. ('173 Patent, claim 1).
• Technical Importance: This patient selection method is framed as important because it directs a potent combination therapy to the patient group most likely to experience a significantly enhanced therapeutic benefit, thereby personalizing treatment and improving outcomes. ('173 Patent, col. 18:1-21).

Key Claims at a Glance

• The complaint focuses on the "Cardiff Patents" generally. ('173 Patent, claim 1) is a representative independent claim.
• Essential elements of independent claim 1 of the '173 Patent include:
  • A method of selecting a subject with metastatic colorectal cancer for a treatment with onvansertib and bevacizumab.
  • Determining if the subject has or has not received any prior treatment with bevacizumab.
  • If the subject has not received any prior treatment with bevacizumab, selecting them for the treatment.
  • If the subject has received prior treatment with bevacizumab, not selecting them for the treatment.
• The complaint does not specify assertion of dependent claims.

III. Analysis of Disputed Allegations

This is a declaratory judgment action concerning inventorship and breach of a license agreement, not a patent infringement action. Therefore, the analysis below summarizes the central factual and legal allegations from the complaint rather than mapping claim elements to an accused product.

The core of the complaint is Cardiff's assertion that the inventions claimed in the '813 and '173 Patents were conceived of solely by its own employees, Drs. Ridinger and Erlander (Compl. ¶2; Compl. ¶30; Compl. ¶105). Cardiff alleges that NMS's employee, Dr. Valsasina, had no involvement in the conception or reduction to practice of these inventions and therefore cannot be a joint inventor under U.S. law (Compl. ¶9; Compl. ¶37). The complaint argues that adding a non-inventor, as NMS demanded, would constitute a false oath and render the patents invalid (Compl. ¶15; Compl. ¶25).

The complaint further alleges that NMS's inventorship claim is a pretext (Compl. ¶112; Compl. ¶119) and part of a "campaign to extract additional money or other value" beyond the terms of the 2017 License Agreement (Compl. ¶39). Cardiff alleges that when it refused to add Dr. Valsasina as an inventor, NMS wrongfully declared a material breach and purported to terminate the License Agreement (Compl. ¶4; Compl. ¶44; Compl. ¶50). Cardiff contends this action by NMS is itself a material breach of the agreement, as Cardiff was acting within its contractually-defined rights to control the prosecution and ownership of its own inventions (Compl. ¶23; Compl. ¶33; Compl. ¶86). The timing of NMS's termination notice is alleged to have been calculated to cause "maximum disruption" to Cardiff's capital-raising and clinical trial efforts (Compl. ¶52; Compl. ¶63).

IV. Key Claim Terms for Construction

• The Term: "who has not received any prior treatment with bevacizumab" ('173 Patent, claim 1) and functionally identical language in the '813 Patent.
• Context and Importance: This negative limitation is central to the claimed invention, defining the specific patient population for whom the treatment method is intended. The inventorship dispute may hinge on this term. To determine if Dr. Valsasina contributed to the "conception," the court must understand what was conceived. Practitioners may focus on this term because if Dr. Valsasina's alleged contributions relate only to the general combination of the drugs, but not to the specific, novel insight of its surprising efficacy in this precisely defined untreated population, her claim to inventorship may be weakened.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party seeking a broad interpretation of "prior treatment" (i.e., any exposure to bevacizumab for any reason) might point to general statements in the specification about angiogenesis and its inhibitors without limitation to a specific disease context. ('813 Patent, col. 17:1-15). This could broaden the universe of what was "conceived."
  • Evidence for a Narrower Interpretation: The claims themselves narrow the scope, referring to a patient who has not received "prior treatment for the metastatic colorectal cancer" ('813 Patent, claim 1). A party could argue this language demonstrates the "conception" was not merely about prior bevacizumab exposure in general, but specifically about its absence in the context of treating the claimed disease. The patent's detailed description emphasizes the surprising results in this specific second-line treatment setting for KRAS-mutated mCRC, further supporting that the inventive concept was tied to this narrow clinical context. ('813 Patent, col. 39:41-49).

V. Other Legal Claims and Allegations

The complaint asserts several counts beyond the request for a declaratory judgment of correct inventorship and no breach of contract.

• Breach of the Implied Covenant of Good Faith and Fair Dealing: Cardiff alleges that NMS breached its duty of good faith and fair dealing, implied under the governing New York law, through a "sustained course of bad-faith conduct designed to deprive Cardiff of the benefit of the License Agreement" (Compl. ¶¶109; 112). The alleged bad-faith acts include demanding Cardiff commit fraud on the Patent Office by adding a non-inventor and using pretextual inventorship claims as a "coercive instrument" to renegotiate financial terms (Compl. ¶112).
• Intentional Interference with Prospective Economic Relations: The complaint alleges NMS intentionally and wrongfully interfered with Cardiff's business relationships with investors, clinical trial investigators, and the FDA (Compl. ¶¶117-119). The alleged interference includes manufacturing a false inventorship dispute and timing the purported termination of the license agreement to disrupt Cardiff's fundraising and clinical trial presentations (Compl. ¶119).
• Wrongful Attempt to Terminate the License Agreement: Cardiff asserts a separate count for breach of contract, alleging that NMS's issuance of the termination letter was itself a material breach because it "lacked valid contractual grounds" and failed to follow the agreement's required procedures for notice and cure (Compl. ¶¶124-125).

VI. Analyst's Conclusion: Key Questions for the Case

This case appears to be primarily a contract dispute centered on the technical and legal standards of patent inventorship. The outcome may turn on the court's resolution of two central questions:

• A core evidentiary question will be one of contribution to conception: Does the evidence show that NMS's employee, Dr. Valsasina, contributed a "significant" inventive concept to the "definite and permanent idea" of the claimed invention, particularly the novel method of treating an anti-angiogenic-naïve patient population, as required to be a joint inventor under U.S. patent law?
• A key contractual question will be one of materiality and pretext: Under New York law, did Cardiff's refusal to add an inventor it believed did not qualify constitute a "material breach" of the License Agreement? Or, as Cardiff alleges, was the inventorship demand a pretext for renegotiating financial terms, making NMS's subsequent termination of the agreement itself a wrongful breach of contract and of the implied covenant of good faith?